% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mhlenbruch:271267,
      author       = {L. Mühlenbruch$^*$ and T. Abou-Kors and M. L. Dubbelaar
                      and L. Bichmann and O. Kohlbacher and M. Bens and J. Thomas
                      and J. Ezić and J. M. Kraus and H. A. Kestler and A. von
                      Witzleben and J. Mytilineos and D. Fürst and D. Engelhardt
                      and J. Doescher and J. Greve and P. J. Schuler and M.-N.
                      Theodoraki and C. Brunner and T. K. Hoffmann and H.-G.
                      Rammensee$^*$ and J. Walz$^*$ and S. Laban},
      title        = {{T}he {HLA} ligandome of oropharyngeal squamous cell
                      carcinomas reveals shared tumour-exclusive peptides for
                      semi-personalised vaccination.},
      journal      = {British journal of cancer},
      volume       = {128},
      number       = {9},
      issn         = {0007-0920},
      address      = {Edinburgh},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2023-00399},
      pages        = {1777-1787},
      year         = {2023},
      note         = {2023 May;128(9):1777-1787},
      abstract     = {The immune peptidome of OPSCC has not previously been
                      studied. Cancer-antigen specific vaccination may improve
                      clinical outcome and efficacy of immune checkpoint
                      inhibitors such as PD1/PD-L1 antibodies.Mapping of the OPSCC
                      HLA ligandome was performed by mass spectrometry (MS) based
                      analysis of naturally presented HLA ligands isolated from
                      tumour tissue samples (n = 40) using immunoaffinity
                      purification. The cohort included 22 HPV-positive (primarily
                      HPV-16) and 18 HPV-negative samples. A benign reference
                      dataset comprised of the HLA ligandomes of benign
                      haematological and tissue datasets was used to identify
                      tumour-associated antigens.MS analysis led to the
                      identification of naturally HLA-presented peptides in OPSCC
                      tumour tissue. In total, 22,769 peptides from 9485 source
                      proteins were detected on HLA class I. For HLA class II,
                      15,203 peptides from 4634 source proteins were discovered.
                      By comparative profiling against the benign HLA ligandomic
                      datasets, 29 OPSCC-associated HLA class I ligands covering
                      11 different HLA allotypes and nine HLA class II ligands
                      were selected to create a peptide
                      warehouse.Tumour-associated peptides are HLA-presented on
                      the cell surfaces of OPSCCs. The established warehouse of
                      OPSCC-associated peptides can be used for downstream
                      immunogenicity testing and peptide-based immunotherapy in
                      (semi)personalised strategies.},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36823366},
      doi          = {10.1038/s41416-023-02197-y},
      url          = {https://inrepo02.dkfz.de/record/271267},
}